NCT02423122View on ClinicalTrials.gov

A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)

PHASE2CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

September 30, 2016

Conditions

Alzheimer's DiseaseMild Cognitive Impairment

Interventions

DRUG

VX-745

Orally-Active Selective P45 MAP Kinase inhibitor

Trial Locations (1)

1081 HV

Alzheimer Research Center, VU Medical Center, Amsterdam

Sponsors

Lead Sponsor

All Listed Sponsors

lead

EIP Pharma Inc

INDUSTRY